iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Michel Detheux, Ph.D., will deliver a presentation on Wednesday, January 15, 2025, at 7:30 AM PST (10:30 AM EST) in San Francisco.

Interested parties can access a live webcast of the presentation through the Investors section of iTeos's website at www.iteostherapeutics.com. The presentation recording will remain available for approximately 30 days after the event.

News Market Reaction

-0.26%

1 alert

-0.26% News Effect

On the day this news was published, ITOS declined 0.26%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST).

A live webcast of the presentation will be available on the Investors section of the Company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

For further information, please contact:

Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

FAQ

When is iTeos Therapeutics (ITOS) presenting at the 2025 J.P. Morgan Healthcare Conference?

iTeos Therapeutics will present on Wednesday, January 15, 2025, at 7:30 AM PST (10:30 AM EST).

How can investors watch iTeos Therapeutics' (ITOS) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast on the Investors section of iTeos's website at www.iteostherapeutics.com.

How long will iTeos Therapeutics' (ITOS) J.P. Morgan presentation replay be available?

The presentation replay will be available for approximately 30 days following the event.

Who is presenting for iTeos Therapeutics (ITOS) at the 2025 J.P. Morgan Healthcare Conference?

Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos Therapeutics, will deliver the presentation.